ArticleEuropean journal of pharmacology2010
Selective MyD88-dependent pathway inhibition by the cyanobacterial natural product malyngamide F acetate.
Article in European journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 62 citations in OpenAlex.
- Multi-Omics Analysis of Gut Microbiome and Host Metabolism in Different Populations of Chinese Alligators (Ecology and evolution · 2025Article
- Isolation and Characterization of the Cyanobacterial Macrolide Glycoside Moorenaside, an Anti-Inflammatory Analogue of Aurisides Targeting the Keap1/Nrf2 Pathway.Journal of natural products · 2024Article
- Marine Microorganism Molecules as Potential Anti-Inflammatory Therapeutics.Marine drugs · 2024Review
- Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease.Natural products and bioprospecting · 2024Review
- Discovery and Anti-Inflammatory Activity of a Cyanobacterial Fatty Acid Targeting the Keap1/Nrf2 Pathway.Marine drugs · 2023Article
- Malyngamide F Possesses Anti-Inflammatory and Antinociceptive Activity in Rat Models of Inflammation.Pain research & management · 2021Article
- Heterologous Expression of Cryptomaldamide in a Cyanobacterial Host.ACS synthetic biology · 2020Article
- Isolation of Isotrichophycin C and Trichophycins G-I from a Collection ofJournal of natural products · 2020Article
- Metabolites from Marine Microorganisms, Micro, and Macroalgae: Immense Scope for Pharmacology.Marine drugs · 2019Review
- Oceans as a Source of Immunotherapy.Marine drugs · 2019Review
- Ketoreductase Domain Dysfunction Expands Chemodiversity: Malyngamide Biosynthesis in the Cyanobacterium Okeania hirsuta.ACS chemical biology · 2018Article
- Cannabinomimetric Lipids: From Natural Extract to Artificial Synthesis.Natural products and bioprospecting · 2018Review
- Marine natural product peptides with therapeutic potential: Chemistry, biosynthesis, and pharmacology.Biochimica et biophysica acta. General subjects · 2018Review
- Modulation of Toll-like receptor signaling in innate immunity by natural products.International immunopharmacology · 2016Review
- Spongosine production by a Vibrio harveyi strain associated with the sponge Tectitethya crypta.Journal of natural products · 2015Article
- Review
- Marine cyanobacterial fatty acid amides acting on cannabinoid receptors.Chembiochem : a European journal of chemical biology · 2012Article
- Honaucins A-C, potent inhibitors of inflammation and bacterial quorum sensing: synthetic derivatives and structure-activity relationships.Chemistry & biology · 2012Article
- Malyngamide 2, an oxidized lipopeptide with nitric oxide inhibiting activity from a Papua New Guinea marine cyanobacterium.Journal of natural products · 2011Article
- Biologically active secondary metabolites from marine cyanobacteria.Current opinion in biotechnology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In response to evolutionary selective pressure, prokaryotes have developed a rich array of secondary metabolites, some of which may be inhibitory to the innate immune system and the inflammatory response in vertebrates. We utilized the RAW264.7 macrophage cell line stimulated with LPS in a nitric oxide (NO) assay to screen for compounds with immunomodulatory activities from a library of marine natural products, and found that the malyngamide structure class, found commonly in the marine cyanobacterium Lyngbya majuscula, has potent activity. Several of the malyngamides were found to possess IC50 values of 5.4-18microM. Malyngamide F acetate exhibited strong concentration-dependent anti-inflammatory activity in the NO assay with an IC50 of 7.1microM and with no cytotoxicity at the concentrations tested. Subsequent real-time PCR of selected genes revealed a unique cytokine profile after LPS stimulation (TLR4) with decreased expression of iNOS, IL-1beta, IL-6, and IL-10, but increased TNF-alpha expression. Additional experiments utilizing CpG and Poly I:C stimulation to selectively activate the MyD88-dependent and -independent pathways via TLR9 and TLR3 substantiated the finding that malyngamide F acetate selectively inhibits the MyD88-dependent pathway. To our knowledge, this is the first report of a natural product inhibiting the MyD88-dependent pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.